Presented by Fondazione Melanoma Onlus in collaboration with the IRCCS Fondazione G. Pascale National Cancer Institute, Sidra Medical and Research Center, the Italian Association of Medical Oncology, and the Society for Immunotherapy of Cancer. Immunotherapy Bridge, which precedes Melanoma Bridge, is a scientific program focused on the application of immunotherapy, not only for melanoma, but also for cancer in general. The program is scheduled for Nov. 28, 2018 - Dec. 1, 2018 in Naples, Italy. SITC Session Agenda – Nov. 28, 2018Evolving Topics in Cancer Immunotherapy: Tumor MicroenvironmentChair: Lisa H. Butterfield, PhD* – University of Pittsburgh
9:15 – 9:35 a.m.
Reprogramming the Tumor Microenvironment and T-cells for Immunotherapy of Ovarian CancerAdekunle Odunsi, MD, PhD* – Roswell Park Comprehensive Cancer Center
9:35 – 9:55 a.m.
The Contribution of Tumor-Residing Dendritic Cells to an Anti-tumor Immune ResponseStefani Spranger, PhD* – Koch Institute for Integrative Cancer Research at MIT
9:55 – 10:15 a.m.
Understanding the Immune Composition and Therapeutic Implications of Human Lung CancerKurt A. Schalper, MD, PhD* – Yale School of Medicine
10:15 – 10:35 a.m.
Effectors and the TMEChrystal Paulos, PhD* – Medical University of South Carolina
10:35 – 10:55 a.m.
Overcoming Metabolic Barriers to Effective Antitumor ImmunityGreg Delgoffe, PhD* – University of Pittsburgh
10:55 – 11:15 a.m.
Discussion on Evolving Topics in Cancer Immunotherapy: Tumor MicroenvironmentLisa H. Butterfield, PhD* – University of Pittsburgh
11:15 – 11:30 a.m.
11:30 a.m. – 12:15 p.m.
12:15 – 12:45 p.m.
New Landscapes in Urothelial Carcinoma**Andrea Necchi – IRCCS Foundation, National Cancer Institute
Discussion on New Landscapes in Urothelial Carcinoma**Giacomo Carteni – Cardarelli HospitalSandro Pignata – National Cancer Institute
12:45 – 1:30 p.m.
*Denotes SITC members**Not included in CME accredited programFor more information, click here.
View the SITC Meeting Code of Conduct.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com